ATLN VX

Actelion Ltd.

Healthcare


Presented:02/27/2015
Price:CHF114.10
Cap:N/A
Current Price:CHF269.00
Cap:$28.97B

Presented

Date02/27/2015
PriceCHF114.10
Market CapN/A
Ent ValueN/A
P/E Ratio21.25x
Book ValueCHF17.40
Div Yield1.15%
Shares O/S111.13M
Ave Daily Vol1,410,000
Short IntN/A

Current

PriceCHF269.00
Market Cap$28.97B
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. It offers Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; and Opsumit, an orally available endothelin receptor antagonist for the treatment of PAH to delay disease progression. The company also provides Veletri, an intravenous prostacyclin for the treatment of PAH to enhance exercise capacity; and Ventavis, an inhaled synthetic analog of prostacyclin for the treatment of PAH to enhance a composite endpoint consisting of exercise tolerance, symptoms, and lack of deterioration. In addition, it offers Valchlor, a chemotherapeutic agent for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Europe, Japan, China, Russia, Mexico, and internationally. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.

Publicly traded companies mentioned herein: Actelion Ltd (ATLN VX), Amgen Inc (AMGN), Gilead Sciences Corporation (GILD)

Highlights

The presenter is short shares of Actelion (ATLN) heading into this year’s American College of Cardiology (ACC) meeting on March 15, which will feature the first scientific presentation of Selexipag (Uptravi) data. Generally speaking, there is a lot of excitement about the top line GRIPHON data (results for ATLN’s oral, selective prostacyclin IP receptor agonist were “highly” statistically significant). He doesn’t necessarily expect the data to disappoint, but there are some risks and expectations (and forecasts) on the Street are simply too high, in his opinion.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.